Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07339384 · ClinicalTrials.gov registry record · NA
Signatera Assessment in Early-Stage Endometrial Cancer
A NA study, sponsored by Natera.
- Not yet
- Registry status
- NA
- Development phase
- 1,010
- Enrollment target
NCT07339384 is a NA study that has not yet begun recruiting, run by Natera. The registered enrollment target is 1,010 participants.
The verdict
NCT07339384, a NA study, has not yet begun recruiting, sponsored by Natera.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 1,010 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. The main question it aims to answer is: • To evaluate if 3-year recurrence-free survival among women with Stage I, high-intermediate risk endometrial cancer who are ctDNA negative after receiving ctDNA-guided observation is non-inferior to adjuvant vaginal brachytherapy (an internal radiation therapy) Researchers will compare high-risk intermediate ctDNA negative participants who are observed to those who receive vaginal brachytherapy to see if they have similar outcomes. Participants will be asked to: * Receive serial ctDNA testing * Visit their study doctor per their standard of care visits about every 3 months for 2 years * Answer a questionnaire about their well-being
Interventions
- DEVICE Signatera Genome ultra-sensitive ctDNA blood test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,010 participants |
| Start Date | 2026-10 |
| Est. Completion | 2034-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07339384
The ClinicalTrials.gov registry entry for NCT07339384 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 1,010 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Natera, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Signatera Genome ultra-sensitive ctDNA blood test is the first listed.
NCT07339384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07339384 about?
NCT07339384 is a clinical study titled "Signatera Assessment in Early-Stage Endometrial Cancer". The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. The main question it aims to answer is: • To evaluate if 3-year recurrence-free survival among women with Stage I, high-intermediate risk endo...
What is the current status of trial NCT07339384?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 1,010 participants. The study started on 2026-10. Estimated completion is 2034-10.
What interventions are being tested in trial NCT07339384?
The interventions under investigation include: Signatera Genome ultra-sensitive ctDNA blood test (DEVICE).
Who is sponsoring clinical trial NCT07339384?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.